COO vs. NVS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at COO and NVS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
COO is a standard domestic listing, while NVS trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | COO | NVS |
|---|---|---|
| Company Name | The Cooper Companies, Inc. | Novartis AG |
| Country | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 13.53 billion USD | 254.99 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | January 21, 1983 | November 7, 1996 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of COO and NVS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | COO | NVS |
|---|---|---|
| 5-Day Price Return | 0.31% | 2.34% |
| 13-Week Price Return | -3.65% | 2.27% |
| 26-Week Price Return | -18.24% | 2.04% |
| 52-Week Price Return | -37.55% | 9.24% |
| Month-to-Date Return | 1.73% | -1.03% |
| Year-to-Date Return | -25.42% | 12.87% |
| 10-Day Avg. Volume | 2.90M | 2.80M |
| 3-Month Avg. Volume | 2.84M | 2.81M |
| 3-Month Volatility | 37.14% | 18.12% |
| Beta | 1.02 | -0.01 |
Profitability
Return on Equity (TTM)
COO
4.97%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
COO’s Return on Equity of 4.97% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
NVS
32.56%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
In the upper quartile for the Pharmaceuticals industry, NVS’s Return on Equity of 32.56% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
COO
10.08%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
COO’s Net Profit Margin of 10.08% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
NVS
24.90%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 24.90% places NVS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
COO
18.31%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
An Operating Profit Margin of 18.31% places COO in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
NVS
30.03%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
An Operating Profit Margin of 30.03% places NVS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | COO | NVS |
|---|---|---|
| Return on Equity (TTM) | 4.97% | 32.56% |
| Return on Assets (TTM) | 3.31% | 13.32% |
| Net Profit Margin (TTM) | 10.08% | 24.90% |
| Operating Profit Margin (TTM) | 18.31% | 30.03% |
| Gross Profit Margin (TTM) | 66.96% | 76.12% |
Financial Strength
Current Ratio (MRQ)
COO
2.12
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
COO’s Current Ratio of 2.12 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
NVS
0.82
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
NVS’s Current Ratio of 0.82 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
COO
0.30
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
COO’s Debt-to-Equity Ratio of 0.30 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
NVS
0.77
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
NVS’s Debt-to-Equity Ratio of 0.77 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
COO
5.87
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
COO’s Interest Coverage Ratio of 5.87 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
NVS
22.55
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
NVS’s Interest Coverage Ratio of 22.55 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | COO | NVS |
|---|---|---|
| Current Ratio (MRQ) | 2.12 | 0.82 |
| Quick Ratio (MRQ) | 0.91 | 0.62 |
| Debt-to-Equity Ratio (MRQ) | 0.30 | 0.77 |
| Interest Coverage Ratio (TTM) | 5.87 | 22.55 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
COO
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
COO currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
NVS
3.27%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
NVS’s Dividend Yield of 3.27% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
COO
2.41%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
COO’s Dividend Payout Ratio of 2.41% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
NVS
102.24%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
NVS’s Dividend Payout Ratio of 102.24% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | COO | NVS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 3.27% |
| Dividend Payout Ratio (TTM) | 2.41% | 102.24% |
Valuation
Price-to-Earnings Ratio (TTM)
COO
33.03
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
COO’s P/E Ratio of 33.03 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
NVS
17.49
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
NVS’s P/E Ratio of 17.49 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
COO
3.33
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
COO’s P/S Ratio of 3.33 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
NVS
4.35
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
NVS’s P/S Ratio of 4.35 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
COO
1.69
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
COO’s P/B Ratio of 1.69 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
NVS
6.06
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
NVS’s P/B Ratio of 6.06 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | COO | NVS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 33.03 | 17.49 |
| Price-to-Sales Ratio (TTM) | 3.33 | 4.35 |
| Price-to-Book Ratio (MRQ) | 1.69 | 6.06 |
| Price-to-Free Cash Flow Ratio (TTM) | 32.71 | 14.21 |